The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank.

ABSTRACT: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used psychopharmaceutical treatment for major depressive disorder (MDD), but individual responses to SSRIs vary greatly. CYP2C19 is a key enzyme involved in the metabolism of several drugs, including SSRIs. Variations in the CYP2C19 gene are associated with differential metabolic activity, and thus differential SSRI exposure; accordingly, the CYP2C19 genotype may affect the therapeutic response and clinical outcomes, though existing evidence of this link is not entirely consistent. Therefore, we analysed data from the UK Biobank, a large, deeply phenotyped prospective study, to investigate the effects of CYP2C19 metaboliser phenotypes on several clinical outcomes derived from primary care records, including multiple meas

SUBMITTER: Wong WLE 

PROVIDER: S-EPMC10535191 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature